References
- Krause JR. Granulocytic sarcoma preceding acute leukemia. A report of six cases. Cancer. 1979;44(3):1017–1021.
- Bekassy AN, Hermans J, Gorin NC, et al. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1996;17(5):801–808.
- Ganzel C, Manola J, Douer D, et al. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN cancer research group trials, 1980–2008. JCO. 2016;34(29):3544–3553.
- Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t (8; 21) differ from those of patients with inv (16): a Cancer and Leukemia Group B study. JCO. 2005;23(24):5705–5717. Sterling LJ,
- Solh M, Solomon S, Morris L, et al. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30(5):333–339.
- DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
- Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
- Reda G, Cassin R, Dovrtelova G, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. haematologica. 2019;104(5):e222–e223.